skip to main content
Idioma:
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Lennox, Jeffrey L, Prof ; DeJesus, Edwin, MD ; Lazzarin, Adriano, Prof ; Pollard, Richard B, Prof ; Madruga, Jose Valdez Ramalho, MD ; Berger, Daniel S, MD ; Zhao, Jing, PhD ; Xu, Xia, PhD ; Williams-Diaz, Angela, BS ; Rodgers, Anthony J, MS ; Barnard, Richard JO, PhD ; Miller, Michael D, PhD ; DiNubile, Mark J, MD ; Nguyen, Bach-Yen, MD ; Leavitt, Randi, MD ; Sklar, Peter, Dr

The Lancet (British edition), 2009-09, Vol.374 (9692), p.796-806 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Eron, Joseph J, Prof ; Young, Benjamin, MD ; Cooper, David A, Prof ; Youle, Michael, MD ; DeJesus, Edwin, MD ; Andrade-Villanueva, Jaime, MD ; Workman, Cassy, MD ; Zajdenverg, Roberto, MD ; Fätkenheuer, Gerd, Prof ; Berger, Daniel S, MD ; Kumar, Princy N, MD ; Rodgers, Anthony J, MS ; Shaughnessy, Melissa A, MS ; Walker, Monica L, BS ; Barnard, Richard JO, PhD ; Miller, Michael D, PhD ; DiNubile, Mark J, MD ; Nguyen, Bach-Yen, MD ; Leavitt, Randi, MD ; Xu, Xia, PhD ; Sklar, Peter, Dr

The Lancet (British edition), 2010-01, Vol.375 (9712), p.396-407 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

Sulkowski, Mark, Prof ; Pol, Stanislas, Prof ; Mallolas, Josep, MD ; Fainboim, Hugo, MD ; Cooper, Curtis, MD ; Slim, Jihad, MD ; Rivero, Antonio, MD ; Mak, Carmen, PhD ; Thompson, Seth, PhD ; Howe, Anita YM, PhD ; Wenning, Larissa, PhD ; Sklar, Peter, MD ; Wahl, Janice, MD ; Greaves, Wayne, Dr

The Lancet infectious diseases, 2013-07, Vol.13 (7), p.597-605 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Eron, Joseph J, Prof ; Rockstroh, Jürgen K, MD ; Reynes, Jacques, Prof ; Andrade-Villanueva, Jaime, MD ; Ramalho-Madruga, Jose Valdez, MD ; Bekker, Linda-Gail, MD ; Young, Benjamin, MD ; Katlama, Christine, MD ; Gatell-Artigas, Jose Maria, MD ; Arribas, Jose R, MD ; Nelson, Mark, MD ; Campbell, Havilland, BS ; Zhao, Jing, PhD ; Rodgers, Anthony J, MS ; Rizk, Matthew L, PhD ; Wenning, Larissa, PhD ; Miller, Michael D, PhD ; Hazuda, Daria, PhD ; DiNubile, Mark J, MD ; Leavitt, Randi, MD ; Isaacs, Robin, MD ; Robertson, Michael N, MD ; Sklar, Peter, MD ; Nguyen, Bach-Yen, Dr

The Lancet infectious diseases, 2011-12, Vol.11 (12), p.907-915 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis
Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis

SKLAR, Peter A ; AGYEMANG, Amma F ; MONASTRA, Rachelle ; KRESS, Diane Rock ; METCALF, Julia A ; ROBINSON, Michael R ; MASUR, Henry ; POLIS, Michael A

AIDS (London), 2004-02, Vol.18 (3), p.567-569 [Periódico revisado por pares]

Hagerstown, MD: Lippincott Williams & Wilkins

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.